Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type |Pathology location|Pathology Description|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study 
|2-10-1-1|1|325|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-2|1|328|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-3|1|334|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-4|1|382|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-5|1|388|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-6|1|405|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-7|1|453|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-8|1|453|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-9|1|474|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-10|1|483|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-11|1|488|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-12|1|497|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 513 - Lymphoid neoplasms|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-13|1|517|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-14|1|523|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-15|1|530|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-16|1|530|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-17|1|532|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-18|1|535|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-19|1|539|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-20|1|544|Neoplasia malignant|Other local manifestations and miscellaneus| benign|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-21|1|555|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-22|1|559|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-23|1|567|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-24|1|600|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-25|1|600|Neoplasia malignant|Nervous system and special sense organs,MA: 0000236 - ear|,MPATH: 218 - neoplasm|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-26|1|605|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-27|1|605|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-28|1|606|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-29|1|607|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-30|1|608|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-31|1|620|Neoplasia systemic|Haematolymphatic system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-32|1|621|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-33|1|626|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-34|1|634|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-35|1|634|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-36|1|637|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-37|1|643|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-38|1|648|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-39|1|650|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-40|1|652|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-41|1|652|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-42|1|654|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-43|1|660|Neoplasia malignant|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-44|1|676|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-45|1|680|Neoplasia malignant|Bloodvessels among cardiovascular system| benign|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-46|1|687|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-47|1|695|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-48|1|698|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-49|1|709|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-50|1|719|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-51|1|721|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-52|1|723|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-53|1|724|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-54|1|724|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-55|1|726|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-56|1|726|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-57|1|726|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-58|1|726|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-59|1|745|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung| metastatic lung tumour,MPATH: 446 - squamous cell carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-60|1|753|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-61|1|761|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-62|1|761|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-63|1|763|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland| metastatic,MPATH: 549 - carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-64|1|763|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-65|1|766|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland| metastatic,MPATH: 549 - carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-66|1|766|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-67|1|779|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-68|1|787|Neoplasia malignant|Reproductive system,MA: 0000411 - testis| metastatic,MPATH: 218 - neoplasm|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-69|1|788|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland| benign,MPATH: 218 - neoplasm|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-70|1|788|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland| benign,MPATH: 218 - neoplasm|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-71|1|799|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-72|1|800|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-73|1|800|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-74|1|803|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-75|1|829|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-76|1|901|Other deterministic changes|Lower respiratory system|n/a|
2-10-1|Ga-Gym0.12-Gy 6,79-86|1| 92|gamma-rays Co-60|6|grays|External exposure| Dose rate 0.025-0.12 Gy/hr|77 (77 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-1-77|1|911|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-1|2|422|Neoplasia malignant|Reproductive system,MA: 0000411 - testis|,MPATH: 218 - neoplasm|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-2|2|519|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-3|2|530|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-4|2|530|Neoplasia malignant|Reproductive system,MA: 0000411 - testis| metastatic,MPATH: 218 - neoplasm|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-5|2|543|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-6|2|564|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-7|2|568|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-8|2|568|Other deterministic changes|Lower respiratory system|n/a|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-9|2|617|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-10|2|648|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-11|2|666|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-12|2|678|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-13|2|678|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-14|2|684|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-15|2|719|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-16|2|730|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-17|2|757|Neoplasia malignant|Other local manifestations and miscellaneus| metastatic|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-18|2|775|Hyperplastic changes|Lower respiratory system|n/a|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-19|2|794|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| metastatic,MPATH: 278 - follicular adenocarcinoma|
2-10-2|Ga-Gy/m0.12-Gy 10,1/81|1| 92|gamma-rays Co-60|10|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-2-20|2|794|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-1|3|306|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-2|3|341|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-3|3|368|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-4|3|375|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-5|3|382|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-6|3|417|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-7|3|450|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-8|3|474|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-9|3|484|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-10|3|498|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-11|3|506|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-12|3|514|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-13|3|535|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-14|3|539|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-15|3|544|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|,MPATH: 322 - teratoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-16|3|551|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-17|3|555|Other deterministic changes|Whole body|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-18|3|582|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-19|3|590|Other deterministic changes|Whole body|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-20|3|620|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-21|3|621|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-22|3|621|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-23|3|621|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-24|3|621|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-25|3|634|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-26|3|635|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-27|3|635|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-28|3|658|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-29|3|702|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-30|3|709|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-31|3|709|Neoplasia malignant|Liver among hepato-pancreatic system diseases| benign|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-32|3|725|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-33|3|738|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-34|3|739|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-35|3|745|Neoplasia malignant|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-36|3|761|Other deterministic changes|Lower respiratory system|n/a|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-37|3|773|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-38|3|784|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-39|3|813|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| metastatic,MPATH: 278 - follicular adenocarcinoma|
2-10-3|Ga-Gy/m0.12-Gy 12,79-83|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-3-40|3|829|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-1|4|304|Other deterministic changes|Lower respiratory system|n/a|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-2|4|401|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-3|4|406|Other deterministic changes|Lower respiratory system|n/a|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-4|4|429|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-5|4|508|Other deterministic changes|Lower respiratory system|n/a|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-6|4|540|Other deterministic changes|Lower respiratory system|n/a|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-7|4|549|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-8|4|570|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-9|4|578|Other deterministic changes|Lower respiratory system|n/a|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-10|4|597|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-11|4|603|Other deterministic changes|Whole body|n/a|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-12|4|622|Other deterministic changes|Lower respiratory system|n/a|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-13|4|653|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-14|4|653|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-15|4|698|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-16|4|698|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-17|4|705|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-18|4|715|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-19|4|715|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-4|Ga-Gy/m0.12-Gy 13,1/80|1| 92|gamma-rays Co-60|13|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-4-20|4|719|Other deterministic changes|Lower respiratory system|n/a|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-1|5|80|Other deterministic changes|Lower respiratory system|n/a|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-2|5|281|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-3|5|286|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-4|5|336|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-5|5|362|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-6|5|378|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-7|5|378|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-8|5|379|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-9|5|392|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-10|5|401|Neoplasia malignant|Integumentary system,MA: 0000151 - skin| benign,MPATH: 219 - adnexal and skin appendage tumor|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-11|5|453|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-12|5|511|Neoplasia benign|Lower respiratory system|n/a|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-13|5|514|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-14|5|537|Other deterministic changes|Lower respiratory system|n/a|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-15|5|562|Other deterministic changes|Lower respiratory system|n/a|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-16|5|569|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-17|5|576|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-18|5|582|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-19|5|583|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-20|5|588|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-21|5|600|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-22|5|606|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-23|5|616|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| metastatic,MPATH: 268 - adenocarcinoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-24|5|629|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-25|5|639|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-26|5|651|Neoplasia malignant|Lower respiratory system|n/a|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-27|5|659|Neoplasia malignant|Lower respiratory system|n/a|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-28|5|659|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ| metastatic,MPATH: 428 - rhabdomyosarcoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-29|5|708|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-30|5|709|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-31|5|719|Neoplasia systemic|Haematolymphatic system|n/a|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-32|5|724|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-33|5|732|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-34|5|746|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-35|5|761|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-5|Ga-Gy/m0.12-Gy 16.5,2/79|1| 92|gamma-rays Co-60|16.5|grays|External exposure| Dose rate 0.12 Gy/hr|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-5-36|5|767|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 409 - fibrous histiocytoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-1|6|42|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-2|6|42|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-3|6|42|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-4|6|79|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-5|6|263|Hyperplastic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-6|6|347|Neoplasia systemic|Haematolymphatic system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-7|6|365|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-8|6|388|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-9|6|430|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-10|6|449|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-11|6|449|Other deterministic changes|Whole body|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-12|6|459|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-13|6|464|Other deterministic changes|Whole body|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-14|6|472|Other deterministic changes|Whole body|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-15|6|474|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-16|6|479|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-17|6|484|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-18|6|498|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-19|6|519|Other deterministic changes|Whole body|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-20|6|523|Neoplasia benign|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-21|6|530|Neoplasia malignant|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-22|6|535|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-23|6|535|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-24|6|535|Neoplasia systemic|Haematolymphatic system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-25|6|542|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-26|6|552|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-27|6|555|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-28|6|555|Other deterministic changes|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-29|6|556|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system| metastatic,MPATH: 551 - sarcoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-30|6|578|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-31|6|580|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-32|6|585|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-33|6|592|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-34|6|593|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-35|6|600|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-36|6|600|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-37|6|634|Neoplasia malignant|Lower respiratory system|n/a|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-38|6|634|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland| metastatic,MPATH: 551 - sarcoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-39|6|648|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-10-6|Ga-Gy/m0.12-Gy 18.5,83|1| 92|gamma-rays Co-60|18.5|grays|External exposure| Dose rate 0.12 Gy/hr|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-6-40|6|660|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-1|7|9|Other deterministic changes|Lower respiratory system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-2|7|13|Other deterministic changes|Lower respiratory system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-3|7|16|Other deterministic changes|Lower respiratory system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-4|7|284|Other deterministic changes|Whole body|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-5|7|347|Neoplasia malignant|Bloodvessels among cardiovascular system| benign|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-6|7|362|Other deterministic changes|Lower respiratory system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-7|7|411|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-8|7|422|Other deterministic changes|Lower respiratory system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-9|7|422|Neoplasia benign|Bloodvessels among cardiovascular system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-10|7|430|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-11|7|495|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-12|7|515|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland| metastatic,MPATH: 551 - sarcoma|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-13|7|529|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-14|7|529|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-15|7|550|Other deterministic changes|Lower respiratory system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-16|7|558|Other deterministic changes|Lower respiratory system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-17|7|561|Other deterministic changes|Whole body|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-18|7|591|Other deterministic changes|Lower respiratory system|n/a|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-19|7|591|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-7|Ga-Gy/m0.12-Gy 20,1/81|1| 92|gamma-rays Co-60|20|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-7-20|7|591|Other deterministic changes|Lower respiratory system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-1|8|21|Other deterministic changes|Lower respiratory system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-2|8|27|Other deterministic changes|Lower respiratory system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-3|8|28|Other deterministic changes|Lower respiratory system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-4|8|29|Neoplasia benign|Lower respiratory system,MA: 0000415 - lung|,MPATH: 240 - hemangioma|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-5|8|34|Other deterministic changes|Lower respiratory system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-6|8|36|Other deterministic changes|Lower respiratory system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-7|8|44|Other deterministic changes|Lower respiratory system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-8|8|55|Other deterministic changes|Lower respiratory system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-9|8|215|Other deterministic changes|Lower respiratory system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-10|8|218|Other deterministic changes|Lower respiratory system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-11|8|282|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 513 - Lymphoid neoplasms|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-12|8|368|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-13|8|373|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-14|8|417|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-15|8|429|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-16|8|429|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-17|8|450|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 513 - Lymphoid neoplasms|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-18|8|474|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-19|8|529|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 551 - sarcoma|
2-10-8|Ga-Gy/m0.12-Gy 26,1/80|1| 92|gamma-rays Co-60|26|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-8-20|8|544|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-1|9|55|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-2|9|60|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-3|9|197|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-4|9|298|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-5|9|341|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-6|9|349|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-7|9|421|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-8|9|438|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-9|9|438|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-10|9|449|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-11|9|449|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-12|9|464|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-13|9|470|Other deterministic changes|Whole body|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-14|9|479|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 549 - carcinoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-15|9|485|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| metastatic,MPATH: 551 - sarcoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-16|9|505|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-17|9|507|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-18|9|519|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-19|9|542|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-20|9|555|Other deterministic changes|Lower respiratory system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-21|9|572|Neoplasia systemic|Haematolymphatic system|n/a|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-22|9|580|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-23|9|592|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-24|9|592|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-25|9|600|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-26|9|615|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-27|9|634|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-28|9|641|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-29|9|700|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-9|Ga-Gy/m0.12-Gy 28,7/79|1| 92|gamma-rays Co-60|28|grays|External exposure| Dose rate 0.12 Gy/hr|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-9-30|9|716|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-1|10|9|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-2|10|10|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-3|10|13|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-4|10|15|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-5|10|15|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-6|10|16|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-7|10|17|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-8|10|17|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-9|10|17|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-10|10|17|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-11|10|20|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-12|10|21|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-13|10|21|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-14|10|21|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-15|10|23|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-16|10|23|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-17|10|24|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-18|10|27|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-19|10|41|Other deterministic changes|Lower respiratory system|n/a|
2-10-10|Ga-Gy/m0.12-Gy 31,1/81|1| 92|gamma-rays Co-60|31|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-10-20|10|298|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-1|11|31|Neoplasia benign|Lower respiratory system,MA: 0000415 - lung|,MPATH: 240 - hemangioma|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-2|11|31|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-3|11|31|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-4|11|31|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-5|11|34|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-6|11|34|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-7|11|34|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-8|11|35|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-9|11|35|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-10|11|36|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-11|11|36|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-12|11|36|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-13|11|37|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-14|11|37|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-15|11|39|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-16|11|44|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-17|11|50|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-18|11|50|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver| benign,MPATH: 242 - hemangiosarcoma|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-19|11|55|Other deterministic changes|Lower respiratory system|n/a|
2-10-11|Ga-Gy/m0.12-Gy 39,1/80|1| 92|gamma-rays Co-60|39|grays|External exposure| Dose rate 0.12 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-11-20|11|55|Other deterministic changes|Lower respiratory system|n/a|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-1|12|247|Other deterministic changes|Lower respiratory system|n/a|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-2|12|317|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-3|12|336|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-4|12|336|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-5|12|392|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-6|12|428|Other deterministic changes|Lower respiratory system|n/a|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-7|12|476|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-8|12|510|Other deterministic changes|Lower respiratory system|n/a|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-9|12|524|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-10|12|582|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-11|12|588|Other deterministic changes|Lower respiratory system|n/a|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-12|12|618|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-13|12|665|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-14|12|665|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-12|Ga-Gy/m15-Gy 8,1/84|1| 92|gamma-rays Co-60|8|grays|External exposure| Dose rate 15 Gy/hr|15 (15 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-12-15|12|665|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-1|13|439|Other deterministic changes|Lower respiratory system|n/a|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-2|13|441|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-3|13|455|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-4|13|502|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-5|13|519|Other deterministic changes|Lower respiratory system|n/a|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-6|13|541|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-7|13|541|Neoplasia malignant|Lower respiratory system|n/a|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-8|13|545|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-9|13|594|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland| benign,MPATH: 549 - carcinoma|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-10|13|603|Other deterministic changes|Lower respiratory system|n/a|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-11|13|603|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-12|13|603|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-13|Ga-Gy/m15-Gy 9,83-84|1| 92|gamma-rays Co-60|9|grays|External exposure| Dose rate 15 Gy/hr|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-13-13|13|666|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-1|14|50|Other deterministic changes|Lower respiratory system|n/a|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-2|14|323|Other deterministic changes|Lower respiratory system|n/a|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-3|14|338|Other deterministic changes|Lower respiratory system|n/a|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-4|14|366|Other deterministic changes|Lower respiratory system|n/a|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-5|14|383|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-6|14|390|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-7|14|416|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-8|14|428|Other deterministic changes|Lower respiratory system|n/a|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-9|14|430|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-10|14|430|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| metastatic,MPATH: 268 - adenocarcinoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-11|14|451|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-12|14|473|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-13|14|522|Other deterministic changes|Lower respiratory system|n/a|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-14|14|525|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-15|14|525|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-16|14|554|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-17|14|554|Neoplasia benign|Bloodvessels among cardiovascular system|n/a|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-18|14|564|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-19|14|564|Neoplasia benign|Lower respiratory system|n/a|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-20|14|564|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-21|14|564|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-22|14|564|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-23|14|602|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-14|Ga-Gy/m10-Gy 9.5,82-84|1| 92|gamma-rays Co-60|9.5|grays|External exposure| Dose rate 10 Gy/hr|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-14-24|14|602|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-1|15|21|Other deterministic changes|Lower respiratory system|n/a|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-2|15|417|Other deterministic changes|Lower respiratory system|n/a|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-3|15|458|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-4|15|493|Other deterministic changes|Lower respiratory system|n/a|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-5|15|493|Other deterministic changes|Lower respiratory system|n/a|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-6|15|515|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-7|15|521|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-8|15|540|Other deterministic changes|Whole body|n/a|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-9|15|548|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-10|15|548|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-11|15|592|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-12|15|614|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-13|15|621|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-14|15|626|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-15|15|626|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-16|15|635|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-17|15|649|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-18|15|698|Other deterministic changes|Lower respiratory system|n/a|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-19|15|731|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-15|Ga-Gy/m10-Gy 12,10/82|1| 92|gamma-rays Co-60|12|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-15-20|15|731|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-1|16|22|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-2|16|23|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-3|16|24|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-4|16|27|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-5|16|27|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-6|16|28|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-7|16|31|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-8|16|31|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-9|16|35|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-10|16|37|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-11|16|41|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-12|16|70|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-13|16|85|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-14|16|288|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-15|16|323|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-16|16|420|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-17|16|430|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-18|16|458|Other deterministic changes|Lower respiratory system|n/a|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-19|16|458|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-10-16|Ga-Gy/m10-Gy 19,5/82|1| 92|gamma-rays Co-60|19|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-16-20|16|558|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-1|17|14|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-2|17|14|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-3|17|14|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-4|17|14|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-5|17|15|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-6|17|15|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-7|17|15|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-8|17|16|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-9|17|20|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-10|17|20|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-11|17|20|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-12|17|20|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-13|17|20|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-14|17|20|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-15|17|22|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-16|17|25|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-17|17|25|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-18|17|27|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-19|17|30|Other deterministic changes|Lower respiratory system|n/a|
2-10-17|Ga-Gy/m5-Gy 24,10/82|1| 92|gamma-rays Co-60|24|grays|External exposure| Dose rate 5 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-17-20|17|32|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-1|18|22|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-2|18|22|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-3|18|22|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-4|18|22|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-5|18|22|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-6|18|22|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-7|18|27|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-8|18|27|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-9|18|28|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-10|18|28|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-11|18|31|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-12|18|34|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-13|18|34|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-14|18|34|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-15|18|34|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-16|18|35|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-17|18|35|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-18|18|36|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-19|18|36|Other deterministic changes|Lower respiratory system|n/a|
2-10-18|Ga-Gy/m10-Gy 28.5,5/82|1| 92|gamma-rays Co-60|28.5|grays|External exposure| Dose rate 10 Gy/hr|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-18-20|18|37|Other deterministic changes|Lower respiratory system|n/a|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-1|19|269|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-2|19|318|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-3|19|357|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-4|19|416|Other deterministic changes|Lower respiratory system|n/a|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-5|19|451|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-6|19|483|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney| metastatic,MPATH: 551 - sarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-7|19|506|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-8|19|530|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-9|19|541|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen| metastatic,MPATH: 242 - hemangiosarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-10|19|560|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle| metastatic,MPATH: 268 - adenocarcinoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-11|19|574|Neoplasia malignant|Liver among hepato-pancreatic system diseases| metastatic|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-12|19|596|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-13|19|608|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-14|19|618|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-15|19|660|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-16|19|695|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-17|19|701|Other deterministic changes|Lower respiratory system|n/a|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-18|19|759|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-19|19|773|Neoplasia malignant|Integumentary system,MA: 0000151 - skin| metastatic,MPATH: 219 - adnexal and skin appendage tumor|
2-10-19|Ga-F6+6-Gy 12,9/85|1| 92|gamma-rays Co-60|6|grays|External exposure| Fractionated 6+6 over 62d, dose rate 0.25 Gy/h|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-20|19|779|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-1|19|269|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-2|19|318|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-3|19|357|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-4|19|416|Other deterministic changes|Lower respiratory system|n/a|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-5|19|451|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-6|19|483|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney| metastatic,MPATH: 551 - sarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-7|19|506|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-8|19|530|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-9|19|541|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen| metastatic,MPATH: 242 - hemangiosarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-10|19|560|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle| metastatic,MPATH: 268 - adenocarcinoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-11|19|574|Neoplasia malignant|Liver among hepato-pancreatic system diseases| metastatic|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-12|19|596|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-13|19|608|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-14|19|618|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-15|19|660|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-16|19|695|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-17|19|701|Other deterministic changes|Lower respiratory system|n/a|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-18|19|759|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-19|19|773|Neoplasia malignant|Integumentary system,MA: 0000151 - skin| metastatic,MPATH: 219 - adnexal and skin appendage tumor|
2-10-19|Ga-F6+6-Gy 12,9/85|2| 154|gamma-rays Co-60|6|grays|External exposure| n/a|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-19-20|19|779|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-1|20|307|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-2|20|328|Other deterministic changes|Lower respiratory system|n/a|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-3|20|330|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-4|20|389|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-5|20|390|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-6|20|390|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-7|20|426|Other deterministic changes|Lower respiratory system|n/a|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-8|20|433|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-9|20|438|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-10|20|446|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|,MPATH: 322 - teratoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-11|20|533|Neoplasia benign|Lower respiratory system|n/a|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-12|20|539|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney| metastatic,MPATH: 549 - carcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-13|20|559|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-14|20|600|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-15|20|605|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-16|20|637|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-17|20|650|Other deterministic changes|Lower respiratory system|n/a|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-18|20|690|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|1| 92|gamma-rays Co-60|10|grays|External exposure| Fractionated 10+6 over 67d, dose rate 0.25 Gy/h|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-19|20|707|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-1|20|307|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-2|20|328|Other deterministic changes|Lower respiratory system|n/a|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-3|20|330|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-4|20|389|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-5|20|390|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-6|20|390|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-7|20|426|Other deterministic changes|Lower respiratory system|n/a|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-8|20|433|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-9|20|438|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-10|20|446|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|,MPATH: 322 - teratoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-11|20|533|Neoplasia benign|Lower respiratory system|n/a|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-12|20|539|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney| metastatic,MPATH: 549 - carcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-13|20|559|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-14|20|600|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-15|20|605|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-16|20|637|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-17|20|650|Other deterministic changes|Lower respiratory system|n/a|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-18|20|690|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-10-20|Ga-F10+6-Gy 16,1/86|2| 159|gamma-rays Co-60|6|grays|External exposure| n/a|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-20-19|20|707|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-1|21|295|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-2|21|346|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-3|21|417|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-4|21|432|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-5|21|438|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-6|21|438|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-7|21|446|Neoplasia systemic|Haematolymphatic system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-8|21|446|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-9|21|446|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-10|21|450|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-11|21|498|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-12|21|507|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen| metastatic,MPATH: 242 - hemangiosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-13|21|551|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-14|21|551|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-15|21|558|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-16|21|568|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-17|21|576|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-18|21|586|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-19|21|586|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-20|21|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-21|21|600|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-22|21|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-23|21|618|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-24|21|638|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-25|21|645|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-26|21|648|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland| metastatic,MPATH: 549 - carcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-27|21|648|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-28|21|648|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|1| 92|gamma-rays Co-60|12|grays|External exposure| Fractionated 12+6+6 over 70d, dose rate 0.25 Gy/h|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-29|21|670|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-1|21|295|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-2|21|346|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-3|21|417|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-4|21|432|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-5|21|438|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-6|21|438|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-7|21|446|Neoplasia systemic|Haematolymphatic system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-8|21|446|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-9|21|446|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-10|21|450|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-11|21|498|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-12|21|507|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen| metastatic,MPATH: 242 - hemangiosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-13|21|551|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-14|21|551|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-15|21|558|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-16|21|568|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-17|21|576|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-18|21|586|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-19|21|586|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-20|21|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-21|21|600|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-22|21|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-23|21|618|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-24|21|638|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-25|21|645|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-26|21|648|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland| metastatic,MPATH: 549 - carcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-27|21|648|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-28|21|648|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|2| 162|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-29|21|670|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-1|21|295|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-2|21|346|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-3|21|417|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-4|21|432|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-5|21|438|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-6|21|438|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-7|21|446|Neoplasia systemic|Haematolymphatic system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-8|21|446|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-9|21|446|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-10|21|450|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract| metastatic,MPATH: 549 - carcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-11|21|498|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-12|21|507|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen| metastatic,MPATH: 242 - hemangiosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-13|21|551|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-14|21|551|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-15|21|558|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-16|21|568|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-17|21|576|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-18|21|586|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-19|21|586|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-20|21|600|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-21|21|600|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-22|21|618|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-23|21|618|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-24|21|638|Other deterministic changes|Lower respiratory system|n/a|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-25|21|645|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-26|21|648|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland| metastatic,MPATH: 549 - carcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-27|21|648|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-28|21|648|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-10-21|Ga-F12+6+6-Gy 22,n/a|3| 232|gamma-rays Co-60|6|grays|External exposure| n/a|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-10-21-29|21|670|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
		
